Actionable insights straight to your inbox

Equities logo

Lexaria’s DehydraTECH Overcomes Key Hurdles for Cannabis Extracts

Lexaria Bioscience Inc. (LXX: CNX) (LXRP) is looking to address the shortcomings of precise dosing across a wide range of delivery systems with its DehydraTECH™ drug delivery platform.

Lexaria Bioscience Inc. LXX:CNX (LXRP) is looking to address the shortcomings of precise dosing
across a wide range of delivery systems with its DehydraTECH™ drug delivery
platform. By combining cannabinoids with fatty acid oil, applying food carrier
particles, and performing a dehydration procedure, the technology masks the
bitter and earthy taste of cannabis oil and ensures quick and effective
transportation into the bloodstream without degradation in the stomach or
liver. Lexaria’s technology now has over 40 patents pending and four patents
already granted in the US.

Cannabis oils and extracts have become tremendously popular following the
legalization of medical and recreational cannabis across a growing number of
jurisdictions. In addition to avoiding the health risks of smoking, cannabis
oils and extracts enable patients and consumers to access precise dosing across
a wide range of delivery systems (e.g. capsules, vape oil, or edibles) for a
consistent experience every time.

Masking Poor Taste

The taste of cannabis oils and extracts depends on the process used to
extract the cannabinoids from the plant but it’s generally described as earthy
and bitter. In fact, new patients and consumers commonly ask how they can mask
the taste of the drug. Many people recommend taking cannabis oils and extracts
with breath mints or other products, but the process can be inconvenient at
best and ineffective at worst.

Lexaria’s DehydraTECH™ technology masks the earthy and bitter flavors of
cannabis oils and extracts using fatty acids. These fatty acids are believed to
block and shunt bound ingredients away from bitter taste receptors, which
eliminates the bad taste in products that incorporate the technology. Non-active
ingredients can then be added to re-flavor the cannabis oils and extracts to
make them more palatable for patients and consumers.

For example, Nuka Enterprises LLC signed a licensing agreement earlier this year
for its cannabis-infused line of chocolates and edible products. The company
had already been utilizing Lexaria’s technology in its award-winning 1906 brand
of chocolates for about two years to mask cannabis flavors and ensure a great
taste — along with the many other benefits of Lexaria’s DehydraTECH™ platform.

Improving Bioavailability

Cannabinoids have poor bioavailability for a couple different reasons:
Orally-consumed cannabinoids are largely destroyed by stomach acids, and those
that aren’t are broken down and altered by first pass metabolism in the liver.
This is why smoking cannabis has a much more immediate effect than
orally-consumed cannabis; it avoids first-pass metabolism and is more quickly
absorbed into the bloodstream through the lungs.

Lexaria’s DehydraTECH™ technology protects orally-consumed cannabinoids
during the stomach transit by co-joining them with lipids. At the same time,
the long-chain fatty acids bypass first pass liver metabolism by design,
enabling the cannabinoids to remain intact upon delivery to the bloodstream.
These two features help increase the bioavailability of cannabinoids and
ultimately make them more effective for medical cannabis patients or recreational
users, and also allow the edible experience to more closely mimic the smoked
experience, for the first time ever.

Management has found that DehydraTECH™ reduces the onset time for cannabis
oils and extracts to just 15 to 20 minutes compared to 60 to 120 minutes for
traditional oral cannabinoids. At the same time, bio absorption improves by
five to 10 times to match that of inhaled cannabinoid delivery mechanisms.
These attributes make the technology ideal for medical uses cases where precise
dosing and immediate onset are critical.

Lexaria’s technology has been repeatedly evaluated by invivo, invitro and
human studies and is currently undergoing additional evaluation by Canada’s
National Research Council.

the interest of full disclosure, we call the reader’s attention to the fact
that, Inc. is compensated by the companies profiled in the
Spotlight Companies section. The purpose of these profiles is to provide
awareness of these companies to investors in the micro, small-cap and growth
equity community and should not in any way be considered as a recommendation to
buy, sell or hold these securities. is not a registered broker
dealer, investment advisor, financial analyst, investment banker or other
investment professional. We are a publisher of original and third party news
and information. All profiles are based on information that is available to the
public. The information contained herein should not be considered to be
complete and is not guaranteed by to be free from misstatement or
errors. The views expressed are our own and not intended to be the basis for
any investment decision. Readers are reminded to do their own due diligence
when researching any companies mentioned on this website. Always bear in mind
that investing in early-stage companies is risky and you are encouraged to only
invest an amount that you can afford to lose completely without any change in
your lifestyle. Equities has been compensated with cash, common shares and/or
warrants for market awareness services provided.

Amid regulatory scrutiny, high volatility and a steep decline in crypto's credibility, is a Bitcoin boom cycle possible?